How common is nausea with lurbinectedin?
Nausea occurs frequently with lurbinectedin (Zepzelca), affecting 57% of patients in clinical trials, with 11% experiencing severe (Grade 3-4) cases.[1] It ranks as one of the drug's most reported gastrointestinal side effects.
What causes nausea during treatment?
Lurbinectedin inhibits transcription and DNA repair in cancer cells, but this mechanism also disrupts rapidly dividing normal cells in the gut, leading to nausea and vomiting.[1][2] Symptoms often start within days of infusion and can persist.
How is nausea managed in patients?
Guidelines recommend premedication with antiemetics like dexamethasone, 5-HT3 antagonists (e.g., ondansetron), and NK1 inhibitors (e.g., aprepitant) before each dose.[1] Supportive care includes hydration and dietary adjustments; severe cases may require dose delays or reductions.
Which patients report nausea most often?
Nausea hits harder in those with small cell lung cancer (SCLC), the primary indication, especially during the first cycle.[1] Pre-existing gastrointestinal issues or concurrent chemotherapy increase risk.
What other GI side effects pair with nausea?
Vomiting follows closely at 45% incidence (9% severe), alongside constipation (37%) and decreased appetite (45%).[1] These often cluster, worsening overall tolerability.
Does nausea improve over time or lead to stopping treatment?
Many patients adapt with prophylaxis, but 5% discontinue lurbinectedin due to GI toxicity, including nausea.[1] Incidence drops slightly after initial cycles.
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/Zepzelca-Prescribing-Information.pdf
[2]: FDA approval summary for lurbinectedin, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf